Antibiotic Resistance and Cancer: Challenges and Potential Solutions (CE Session)
Description:
Date/Time: April 11, 2024 | 12:15 - 12:45 pm ET
Antibiotics have been critical for treating the infectious complications that can occur in individuals who are being treated for malignancy. These lifesaving medications are becoming less effective as rates of resistance increase. This session will describe the state of emerging resistance seen in cancer patients and discuss potential future approaches to help reduce resistance in this vulnerable population.
Learning Objectives:
At the end of this session, the learner will be able to:
- Describe the epidemiology of antibiotic resistance in patients with cancer;
- Discuss newer antimicrobial strategies that could be used to treat drug-resistant infections in these patients.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
David Greenberg, MD
Professor of Infectious Diseases and Microbiology
UT Southwestern
David Greenberg, M.D., is Professor of Infectious Diseases and Microbiology at UT Southwestern Medical Center. He is also a Distinguished Teaching Professor and a past recipient of the Regents’ Outstanding Teaching Award for the UT System.
Dr. Greenberg is a first-generation Texan. After graduating from the Johns Hopkins University, he returned to Houston to attend Baylor College of Medicine where he completed medical school, an internal medicine residency, and served as a Chief Resident. Dr. Greenberg then received his Infectious Diseases training at the National Institutes of Health and joined the faculty at UT Southwestern in 2010.
A board-certified Infectious Diseases physician-scientist, Dr. Greenberg spends much of his clinical time on the Transplant Infectious Diseases consultation service at Clements University Hospital. He specializes in the care of the immunocompromised host, a patient population that is at high risk for infectious complications, including with drug-resistant pathogens.
Dr. Greenberg’s research interests revolve around the increasing crisis of antibiotic resistance. He is actively involved in developing innovative strategies to develop new therapeutics to combat drug-resistant bacteria. In addition, he is working on genomic approaches to more accurately predict antibiotic resistance in medically important human pathogens. He currently serves on an NIH Grant Review Panel on anti-infectives. Dr. Greenberg is widely published and is nationally known for his research. He is a Fellow in the Infectious Diseases Association of America and currently serves on the Antibiotic Resistance Committee. He serves as a reviewer for numerous Infectious Diseases publications and is an author for one of the leading infectious diseases textbooks.
Dr. Greenberg is presenting Antibiotic Resistance and Cancer: Challenges and Potential Solutions, at Sepsis Alliance AMR Conference 2024.